PSG.DE stock trades at €29.00 pre-market on 02 Feb 2026 as volume jumps to 12,424, signalling a short-term oversold bounce opportunity. The XETRA-listed PharmaSGP Holding SE shows support near the Keltner lower band at €28.20 and a 50-day average at €28.52, framing a low-risk entry for traders seeking a bounce. We analyse valuation, technical levels, and a realistic price path for this Germany-listed healthcare small cap.
PSG.DE stock technicals and intraday context
Price is €29.00 with day range €28.60–€29.00 and a relative volume of 2.30, indicating higher-than-normal trading interest. The Keltner channel sits lower €28.20 / middle €29.00 / upper €29.80, placing the current quote on the channel middle and within a tight risk band.
Short-term support is €28.20 and immediate resistance at the 50-day average €28.52 and a near-term target of €31.50. Volume spike plus price stability near the lower channel suggests an oversold bounce setup for traders sizing positions with a tight stop under €28.00.
PSG.DE stock fundamentals and valuation
PharmaSGP (PSG.DE) reports EPS €1.68 and a market price of €29.00, implying a trailing PE near 17.26 based on the provided quote. Market cap is €333,862,500 and shares outstanding are 11,512,500.
Key ratios show price-to-sales 3.55, price-to-book 9.12, return on equity 44.29%, current ratio 2.68, and free cash flow yield 6.52%. Low net debt and interest coverage 8.83 reduce balance-sheet risk, but the elevated PB suggests a premium for margins and brand-driven sales.
Meyka AI rates PSG.DE with a score out of 100
Meyka AI rates PSG.DE with a score out of 100: 75.07 / 100 (Grade B+) — Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score reflects strong margins and cash flow but higher price-to-book and inventory days that raise valuation watchfulness.
DISCLAIMER: These grades are model outputs and not guarantees. We are not financial advisors.
Meyka AI’s forecast model projects price paths for PSG.DE stock
Meyka AI’s forecast model projects a 1-year €27.36 (-5.64% vs €29.00), 3-year €29.48 (+1.65%), and 5-year €31.56 (+8.84%). Forecasts show a modest downside in the next 12 months but gradual upside over multi-year horizons as margins and cash flows compound.
Forecasts are model-based projections and not guarantees. Use them alongside fundamental and technical triggers for an oversold bounce trade.
Trade plan: oversold bounce strategy for PSG.DE stock
A disciplined oversold bounce trade targets €31.50 near term and €33.00 as an extended move, with a stop-loss under €28.00 to limit downside. Position size should reflect the small-cap nature and average daily volume 5,399, currently trading at 12,424.
Risk factors include inventory days 400.36 and price-to-book 9.12 that can amplify downside if demand weakens. Use a 1:2 risk/reward and watch sector moves in Healthcare across German markets for confirmation.
Catalysts, risks and sector context for PSG.DE stock
Catalysts: stronger-than-expected OTC sales in European markets, expanded distribution to pharmacies, and margin recovery could fuel a sustained bounce. Recent revenue growth was 17.55% year over year to FY 2024, supporting earnings momentum.
Risks: elevated inventory days, premium valuation metrics, and weaker European OTC demand could reverse gains. Healthcare sector performance in Germany is modest year-to-date, so watch cross-sector flows and regulatory news.
Final Thoughts
PSG.DE stock at €29.00 pre-market on 02 Feb 2026 shows a clear short-term oversold bounce setup with support at €28.20 and a near-term target of €31.50. Valuation mixes attractive cash flow yields (6.52%) and high ROE (44.29%) against a rich price-to-book 9.12 and long inventory days 400.36. Meyka AI’s grade (B+, 75.07/100) highlights strong profitability and low leverage but flags valuation risk. Meyka AI’s forecast projects €27.36 in one year (-5.64%) and €31.56 in five years (+8.84%); these are model projections, not guarantees. For traders using an oversold bounce strategy, a tight stop below €28.00, target €31.50, and position sizing that respects volume and liquidity provide a balanced approach. Monitor XETRA trading and quarterly updates for confirmation, and consult your portfolio risk limits before acting. For the company site and live quotes, see PharmaSGP website and the XETRA market page. Also review the stock page on Meyka for live analytics: PharmaSGP on Meyka.
FAQs
Is PSG.DE stock a buy right now?
PSG.DE stock presents a short-term oversold bounce with a near-term target €31.50, but valuation and inventory risks remain. Meyka AI gives a B+ (BUY) grade, so traders may consider small, disciplined positions with a stop under €28.00.
What are realistic price targets for PSG.DE stock?
Near-term technical target is €31.50 and an extended target €33.00 if momentum holds. Meyka AI’s 1-year model price is €27.36 and 5-year €31.56, which are model projections, not guarantees.
Which ratios matter most for PSG.DE stock?
Key ratios: PE 17.26, EPS €1.68, P/S 3.55, P/B 9.12, ROE 44.29%, and free cash flow yield 6.52%. Combine these with liquidity (avg vol 5,399) when sizing positions.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)